Eurofins Scientific SE
PAR:ERF
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44.19
61.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Eurofins Scientific SE
Net Income (Common)
Eurofins Scientific SE
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Eurofins Scientific SE
PAR:ERF
|
Net Income (Common)
€325.9m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
Eurofins Scientific SE
Glance View
In the intricate realm of scientific services, Eurofins Scientific SE emerges as a quintessential powerhouse, orchestrating a symphony of analysis and testing across various industries. Founded in 1987, Eurofins began its journey with a focus on groundbreaking scientific methods for food and agriculture sectors. However, it rapidly diversified its expertise, leveraging its analytical prowess to expand into pharmaceuticals, environmental testing, and clinical diagnostics. The company operates through a network of laboratories scattered across the globe, each one serving as a beacon of quality and precision, embodying Eurofins' commitment to safeguarding consumer health, ensuring product safety, and supporting regulatory compliance. This robust infrastructure allows Eurofins to produce a constant stream of detailed and reliable test results, fueling its reputation and securing its place in the global market. Eurofins generates revenue primarily through its comprehensive suite of testing services, which cut across multiple sectors. Clients range from large corporations and government bodies to individual consumers who require specific tests. The company capitalizes on its broad spectrum of specialized tests, from determining the complex composition of food products to detecting elusive contaminants in pharmaceuticals and performing critical genetic screenings. This creates a diversified revenue stream that minimizes dependency on any single industry or service line. Eurofins' ability to continuously innovate and adapt its offerings ensures an ongoing inflow of clients seeking unparalleled testing accuracy and expertise. The combination of this vast service portfolio and relentless pursuit of scientific advancement underpins Eurofins' impressive financial performance and solidifies its pivotal role in the scientific services industry.
See Also
What is Eurofins Scientific SE's Net Income (Common)?
Net Income (Common)
325.9m
EUR
Based on the financial report for Jun 30, 2024, Eurofins Scientific SE's Net Income (Common) amounts to 325.9m EUR.
What is Eurofins Scientific SE's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
18%
Over the last year, the Net Income (Common) growth was -21%. The average annual Net Income (Common) growth rates for Eurofins Scientific SE have been -27% over the past three years , 18% over the past five years , and 18% over the past ten years .